Revenue, 2025

USD 5.42 Bilion

Forecast, 2035

USD 12.55 Billion

CAGR, 2026-2035

8.76%

Report Coverage

Global

Hereditary Angioedema Therapeutics Market Trends for 2026

The global hereditary angioedema therapeutics market size was estimated at USD 5.42 billion in 2025 and is predicted to increase from USD 5.89 billion in 2026 to approximately USD 12.55 billion by 2035, expanding at a CAGR of 8.76% from 2026 to 2035. Growing health awareness and early hereditary angioedema (HAE) diagnosis are increasing the demand for hereditary angioedema therapeutics. The growth in R&D activities, collaborations, expanding healthcare, government support, and new product launches is also enhancing the market growth.

Key Takeaways

• Hereditary angioedema therapeutics sector pushed the market to USD 5.89 billion by 2026.
• Long-term projections show USD 12.55 billion valuation by 2035.
• Growth is expected at a steady CAGR of 8.76% in between 2026 to 2035.
• North America held the major revenue share of 41% in the global hereditary angioedema therapeutics market in 2025.
• Asia Pacific held 18% share of the market in 2025 and is expected to grow at the fastest CAGR of 10.20% during the forecast period.
• By drug class type, the C1 esterase inhibitors segment held a dominant revenue share of 48% of the market in 2025.
• By drug class type, the kallikrein inhibitors segment held 32% of market share in 2025 and is expected to grow at the fastest CAGR of 10.80% during the forecast period.
• By route of administration type, the intravenous segment held a dominant revenue share of 46% of the market in 2025.
• By route of administration type, the oral segment held 16% of market share in 2025 and is expected to grow at the fastest CAGR of 11.20% during the forecast period.
• By treatment type, the prophylactic treatment segment held a dominant revenue share of 58% of the market in 2025 and is expected to grow at the fastest CAGR of 9.90% during the forecast period.
• By distribution channel type, the hospital pharmacies segment held a dominant revenue share of 52% of the market in 2025.
• By distribution channel type, the online pharmacies segment held 20% of the hereditary angioedema therapeutics market share in 2025 and is expected to grow at the fastest CAGR of 10.50% during the forecast period.
• By end user, the hospitals segment held a dominant position in the market with a share of 55% in 2025.
• By end user, the homecare settings segment held the second-largest share of 18% of the market in 2025 and is expected to grow at the fastest CAGR of 10.90% during the forecast period.

What are the Hereditary Angioedema Therapeutics?

The hereditary angioedema therapeutics market is driven by a growing shift towards patient-friendly and long-term treatment options. The hereditary angioedema therapeutics encompass medications used for the treatment or prevention of swelling attacks due to a rise in bradykinin levels caused by dysfunction or deficiency of C-1 inhibitors. They are used to treat acute or frequent attacks, prevent airway obstruction, and prevent long-term complications.

AI Technological Shifts in the Hereditary Angioedema Therapeutics Market

AI offers a wide range of applications in the development of hereditary angioedema therapeutics by identifying new targets and accelerating drug discovery and development. It also helps in early disease diagnosis, prevention of attack risks and drug adverse effects, and monitoring disease progression. It also helps in personalized treatment planning and clinical trial optimization, where it offers smart treatment tracking and reminder systems, improving patient adherence to the treatment.

What are the Trends & Future Outlook of the Hereditary Angioedema Therapeutics Market?

Rising Demand for Advanced Therapies

The growing health awareness and R&D activities are driving the adoption and development of new hereditary angioedema therapeutics. Products such as Kallikrein inhibitor, recombinant and plasma-free C1 inhibitors, and bradykinin pathway blockers are being used for better attack control.

Expanding Pipeline

The companies are developing next-generation therapeutics with oral or subcutaneous administration to enhance patient adherence and outcomes. This is promoting the development of new RNA-based therapies, gene therapies, and monoclonal antibodies.

Technological Advancements

Growing technological advancements are increasing the use of various telehealth platforms and digital tools for patient-centric HAE treatment. This is driving the adoption of attack tracking devices, early prediction systems, and treatment monitoring systems.

Key Indicators and Highlights

Segmental Insights

By Drug Class Insights

The C1 Esterase Inhibitors Segment Dominated the Market With 48% in 2025

The C1 esterase inhibitors segment led the hereditary angioedema therapeutics market with 48% share in 2025, due to established clinical efficacy, which increased the physician preference. The presence of plasma-derived therapies also remained widely adopted globally. Strong reimbursement support also sustained demand.

The kallikrein inhibitors segment held the second-largest share of 32% of the market in 2025 and is expected to witness the fastest growth with a CAGR of 10.80% during the forecast period, driven by increasing adoption of targeted therapies, which enhances patient outcomes. Advancements in monoclonal antibodies also boost their innovations. Favorable dosing frequency improves patient compliance.

The bradykinin B2 receptor antagonists segment held 12% of the hereditary angioedema therapeutics market share in 2025, due to their rapid symptom relief, which supports emergency usage. Their strong presence in acute attack management also drives demand. Increasing diagnosis rates also boost their utilization.

The others segment held 8% of the market share in 2025, as legacy therapies sustain their use in low-resource settings. Their cost-effectiveness also increases their adoption rates. Their oral administration and widespread availability also increase their use.

By Route of Administration Insights

The Intravenous Segment Dominated the Market With 46% in 2025

The intravenous segment accounted for the highest revenue share of 46% of the hereditary angioedema therapeutics market in 2025, due to long-standing clinical use, which ensured their strong adoption. Their high efficacy in acute care settings also supported their increased demand. Widespread availability across hospitals globally has also increased their use.

The subcutaneous segment held the second-largest share of 38% of the market in 2025, due to its patient-friendly administration. They also help in reducing hospital visits and enhancing patient convenience. Their growing use in prophylactic therapies is also accelerating their growth.

The oral segment held 16% of the hereditary angioedema therapeutics market share in 2025 and is expected to show the highest growth with a CAGR of 11.20% during the forecast period, due to rising pipeline innovations that are expanding oral options. They also help in improving patient adherence, driving their preference. Ease of administration also supports rapid uptake.

By Treatment Type Insights

The Prophylactic Treatment Segment Dominated the Market With 58% in 2025

The prophylactic treatment segment held a major revenue share of 58% of the hereditary angioedema therapeutics market in 2025 and is expected to expand rapidly with a CAGR of 9.90% during the forecast period, due to increased focus on prevention, which reduces attack frequency. They also promoted the use of long-term therapies, which improved the quality of life. Strong pipeline expansion also accelerated their growth.

The on-demand treatment segment held the second-largest share of 42% of the market in 2025, as they are essential for acute attack management. They are widely used in emergency scenarios. At the same time, strong clinical necessity also maintains its stable demand.

By Distribution Channel Insights

The Hospital Pharmacies Segment Dominated the Market With 52% in 2025

The hospital pharmacies segment contributed the biggest revenue share of 52% of the hereditary angioedema therapeutics market in 2025, due to centralized treatment protocols, which increased hospital dispensing. The effective management of high-cost biologics also increased their preference. Strong reimbursement frameworks also supported their growth.

The retail pharmacies segment held the second-largest share of 28% of the market in 2025, due to expanding access to chronic therapies, which boosts retail sales. Increasing outpatient treatments also supports their demand. Improved awareness enhances availability, which increases the dependence on retail pharmacies.

The online pharmacies segment held 20% of the hereditary angioedema therapeutics market share in 2025 and is expected to gain the highest share with a CAGR of 10.50% during the forecast period, due to digital healthcare expansion, which is increasing the HAE therapeutics accessibility. Their home deliveries are also supporting chronic disease management. Growing patient preference for convenience also drives adoption.

By End User Insights

The Hospitals Segment Dominated the Market With 55% in 2025

The hospitals segment held the largest revenue share of 55% of the hereditary angioedema therapeutics market in 2025, as they were considered the primary centers for diagnosis and acute treatment of HAE. They offered access to advanced biologics, which increased their usage. Strong infrastructure also contributed to their dominance.

The specialty clinics segment held the second-largest share of 27% of the market in 2025, due to increasing specialization, which improves treatment outcomes. Their focused care enhances patient monitoring, promoting their use. A rising number of clinics is also driving their growth.

The homecare settings segment held 18% of the hereditary angioedema therapeutics market share in 2025 and is expected to grow with the fastest CAGR of 10.90% during the forecast period, due to a shift toward self-administration. They enhance patient convenience, reducing hospital dependency. Increasing advancements in subcutaneous therapies also drive home care expansion.

Regional Insights

High Diagnosis Rates Drive North America

North America dominated the hereditary angioedema therapeutics market with 41% in 2025, due to high diagnosis rates and the presence of advanced healthcare infrastructure. Strong presence of key players also increased the hereditary angioedema therapeutics innovation. Favorable reimbursement policies also enhanced their access, which contributed to the market growth.

U.S. Market Trends

The largest patient pool with high awareness in the U.S. is increasing the demand for hereditary angioedema therapeutics. Strong pipeline and FDA approvals are also supporting their innovations. Premium pricing is also supporting their revenue growth, where the companies are also contributing to their increased innovations.

Rising Awareness Boost Asia Pacific

Asia Pacific held 18% share of the hereditary angioedema therapeutics market in 2025 and is expected to grow at the fastest CAGR of 10.20% during the forecast period, due to rising awareness of rare diseases, which boosts early hereditary angioedema diagnosis. Expanding healthcare infrastructure is also increasing their access to therapeutics. Increasing investments in biologics are also enhancing the market growth.

China Market Trends

Large patient population in China drives demand for hereditary angioedema therapeutics. Expanding healthcare is improving their access, and growing health awareness is also promoting their rapid growth. Growing government initiatives and increasing rare disease R&D activities are also increasing their innovations.

Hereditary Angioedema Therapeutics Market Value Chain Analysis

R&D

• The R&D of the hereditary angioedema therapeutics focuses on the development of long-acting monoclonal antibodies, oral on-demand treatments, and one-time CRISPR/RNA-based gene therapies.
• Key players: KalVista Pharmaceuticals, Astria Therapeutics, Intellia Therapeutics.

Clinical Trials and Regulatory Approvals

• The safety profile, symptom relief duration, reduction in monthly attack rates, and quality of life improvements are evaluated in the clinical trials and regulatory approvals of the hereditary angioedema therapeutics.
• Key players: KalVista Pharmaceuticals, Takeda Pharmaceuticals, and CSL Behring.

Packaging and Serialization

• The packaging and serialization of hereditary angioedema therapeutics involves the use of prefilled syringes, 2D DataMatrix barcodes, and tamper-evident seals.
• Key players: Takeda Pharmaceuticals, CSL Behring, BioCryst Pharmaceuticals.

Distribution to Hospitals, Pharmacies

• The specialty pharmacies and authorized wholesalers are responsible for the distribution of the hereditary angioedema therapeutics to the hospitals and pharmacies.
• Key players: Takeda Pharmaceuticals, CSL Behring, BioCryst Pharmaceuticals.

Patient Support and Services

• The home injection training, financial assistance, 24/7 clinical support, and insurance navigation are provided in the support and services of the hereditary angioedema therapeutics.
• Key players: Takeda Pharmaceuticals, CSL Behring, BioCryst Pharmaceuticals.

Who are the Hereditary Angioedema Therapeutics Market Top Vendors and What are Their Offerings?

SWOT Analysis

Strengths

• The hereditary angioedema therapeutics help in the prevention and treatment of swelling attacks, increasing their demand.
• They offer targeted actions that help in reducing airway obstructions.
• Their faster symptom relief, safety, and self-administration approaches also increased their adoption rates.
• They also offer personalized treatment options and long-term prophylaxis prevention options, increasing their demand.

Weaknesses

• High treatment cost acts as the major weakness in the hereditary angioedema therapeutics market, limiting their adoption rates.
• Limited awareness and need for long-term treatment also reduce their use.

Opportunities

• Growing health awareness is increasing the hereditary angioedema diagnostic rates, increasing the demand for their therapeutics.
• Increasing demand for long-term prophylaxis therapies is also increasing their adoption rates.
• Growing advancements in targeted biologic and personalized medicines are also increasing their use.
• Expanding pediatric treatment, gene therapies, and orphan drugs are also increasing their innovations.

Threats

• Complex production and demand for expensive raw materials and processes increase the manufacturing cost, limiting their innovations.
• Batch variability and risk of contamination also reduce the development of new hereditary angioedema therapeutics.

What are the Recent Developments in the Hereditary Angioedema Therapeutics Market?

• In March 2026, the interim data from a Phase 1/2 trial of onvuzosiran (ADX-324) developed by Adarx Pharmaceuticals was presented at the American Academy of Allergy, Asthma & Immunology annual scientific meeting, held in Philadelphia, Pennsylvania. The data revealed that the products showed tolerance and lowered the kallikrein levels, which is a protein triggering HAE swelling attacks, and with the use of this product, the frequency of swelling attacks will be reduced.
• In February 2025, the initiation of the ALPHA-ORBIT Phase 3 clinical trial of navenibart was announced by Astria Therapeutics, Inc. The product is developed to offer rapid and sustained HAE attack prevention, which will be administered every 3 months (Q3M) and every 6 months (Q6M).

Segments Covered in the Report

By Drug Class

• C1 Esterase Inhibitors
  • Plasma-Derived C1-INH
  • Recombinant C1-INH
• Kallikrein Inhibitors
  • Monoclonal Antibodies
  • Small Molecule Inhibitors
• Bradykinin B2 Receptor Antagonists
• Others
  • Androgen Derivatives
  • Antifibrinolytics

By Route of Administration

• Intravenous
• Subcutaneous
• Oral

By Treatment Type

• On-demand Treatment
• Prophylactic Treatment
  • Short-term Prophylaxis
  • Long-term Prophylaxis

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By End User

• Hospitals
• Specialty Clinics
• Homecare Settings

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA